GSK boosts growth with oncology pipeline expansion and £1.9B cost savings reinvested in drug development
GSK is expanding its oncology drug pipeline through acquisitions and promising clinical trial results, including a 94% response rate for its lung cancer drug Jideytro. The company plans to save nearly £1.90 billion in costs, reinvesting these funds t...
